Contributions
Abstract: EP1376
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Objective: The appropriate measurement and management of symptoms related to multiple sclerosis (SymR-MS) could improve the quality of life of patients. Clinician-rated measures of these symptoms purport to be objective but do not measure the patient's experience and may not be sensitive to changes that are meaningful to the patient. In addition, obtaining this crucial information is often time-consuming and therefore not routinely collected. We present our experience in the systematic data collection of a total of 10 validated scales for different SymR-MS from an electronic device. The patients complete the scales in the waiting room and the data are automatically uploaded to the electronic medical records being evaluated in real time by the neurologist.
Material and methods: The analysis included MS clinical form, Disease Modifying Therapies (DMT), administration route and a total of 10 patient-based measures including Numeric Rating Scale (NRS) for Spasticity, Penn Spasms Frequency Scale, Bladder Control Scale, Sleep Quality Scale, Gait Quality Scale, NRS for pain, Barthel index, Fatigue Severity Scale, The European Quality of Life-5 dimensions and Sexual Satisfaction Scale.
Results: 20 patients with MS (80% RRMS, 20% SPMS) and 13 controls were analyzed. Most of patients (75%) were treated with first line DMT (44% oral, 33% subcutaneous). Patients with MS had a higher Kurtzke scale (EDSS) (p>0.001), increased spasticity (p=0.006) and greater gait difficulty (p=0.007) than controls. Patients with SPMS complained of greater spasticity (p=0.001), frequency of spasms (p=0.002), gait difficulty (p=< 0.001), degree of dependence (p=0.027), worse bladder control (p=0.028) and worse sexual satisfaction (p=0.034) than controls. When comparing SPMS and RRMS patients, these differences were significant only for gait difficulty (p=0.027). Patients with EDSS >3.0 complained of worse spasticity (p=0.007), bladder control (p=0.009) and gait difficulty (p=0.002) compared to patients with EDSS < 3.0. No significant differences were observed with respect to DMT or route of administration. In the correlation analysis, the parameters related to a worse quality of life were the sleep disorders and the pain.
Conclusions: The application of an electronic method in the collection of SymR-MS provides crucial information in real time during the visit of the patient. In our experience allows us to systematically quantify these symptoms and make appropriate therapeutic decisions.
Disclosure:
Robles-Cedeño, René reports no disclosures.
Perkal Rug, Héctor reports no disclosures.
Quintana Camps, Ester reports no disclosures.
Merchán Ruiz, Miguel reports no disclosures.
Lluís Ramió-Torrentà: has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.
Abstract: EP1376
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Objective: The appropriate measurement and management of symptoms related to multiple sclerosis (SymR-MS) could improve the quality of life of patients. Clinician-rated measures of these symptoms purport to be objective but do not measure the patient's experience and may not be sensitive to changes that are meaningful to the patient. In addition, obtaining this crucial information is often time-consuming and therefore not routinely collected. We present our experience in the systematic data collection of a total of 10 validated scales for different SymR-MS from an electronic device. The patients complete the scales in the waiting room and the data are automatically uploaded to the electronic medical records being evaluated in real time by the neurologist.
Material and methods: The analysis included MS clinical form, Disease Modifying Therapies (DMT), administration route and a total of 10 patient-based measures including Numeric Rating Scale (NRS) for Spasticity, Penn Spasms Frequency Scale, Bladder Control Scale, Sleep Quality Scale, Gait Quality Scale, NRS for pain, Barthel index, Fatigue Severity Scale, The European Quality of Life-5 dimensions and Sexual Satisfaction Scale.
Results: 20 patients with MS (80% RRMS, 20% SPMS) and 13 controls were analyzed. Most of patients (75%) were treated with first line DMT (44% oral, 33% subcutaneous). Patients with MS had a higher Kurtzke scale (EDSS) (p>0.001), increased spasticity (p=0.006) and greater gait difficulty (p=0.007) than controls. Patients with SPMS complained of greater spasticity (p=0.001), frequency of spasms (p=0.002), gait difficulty (p=< 0.001), degree of dependence (p=0.027), worse bladder control (p=0.028) and worse sexual satisfaction (p=0.034) than controls. When comparing SPMS and RRMS patients, these differences were significant only for gait difficulty (p=0.027). Patients with EDSS >3.0 complained of worse spasticity (p=0.007), bladder control (p=0.009) and gait difficulty (p=0.002) compared to patients with EDSS < 3.0. No significant differences were observed with respect to DMT or route of administration. In the correlation analysis, the parameters related to a worse quality of life were the sleep disorders and the pain.
Conclusions: The application of an electronic method in the collection of SymR-MS provides crucial information in real time during the visit of the patient. In our experience allows us to systematically quantify these symptoms and make appropriate therapeutic decisions.
Disclosure:
Robles-Cedeño, René reports no disclosures.
Perkal Rug, Héctor reports no disclosures.
Quintana Camps, Ester reports no disclosures.
Merchán Ruiz, Miguel reports no disclosures.
Lluís Ramió-Torrentà: has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.